A polypill conundrum – Optimising cardiovascular risk management

Optimally manage the ‘terrible twins’ of CVD: improve adherence to treatment for the preventable risks of raised LDL-C and BP using effective and well tolerated dual- and triple-combination therapies with complementary actions
Learning objectives:
You will learn
- Why dyslipidaemia and hypertension are the key drivers of atherosclerotic cardiovascular disease
- Approaches to initial evaluation and treatment initiation for hypertensive patients with or without hypercholesterolaemia
- The evidence supporting safety and efficacy of antihypertensive therapies for reducing
cardiovascular risk, and using complementary mechanisms of action to improve cardiovascular outcomes - The importance of addressing poor/non-adherence to therapy and the multifold benefits of using single-pill combination therapies.
To access this module, please register or login: